hims and hers semaglutide & abandons copycat weight-loss drug in face of FDA probe Hims & Hers shares fall

they are safe and effective in the majority of patients with type 2 diabetes mellitus

Ben Weiss Express Scripts is the largest pharmacy benefit management organization in the United States

In a New York Times opinion column explaining why the FDA is taking action this week, Commissioner Marty Makary highlighted online pharmacies marketing drugs without presenting an adequate balance of risks, and in particular a Super Bowl ad from Hims & Hers parading the benefits of GLP-1 drugs without any mention of side effects. But the compounding letters scope is narrower than that messaging suggests

Reconstitution itself requires attention to detail

Higher glucagon receptor occupancy creates greater sustained metabolic demand

Throughout the year, Lilly and Novo Nordisk maintained their dominance in the GLP-1 obesity market but grappled with competition from GLP-1 compounding companies that arose from tirzepatide and semaglutide shortages